Trimix

TriMix – a rationally designed novel adjuvant

  • NDendritic cell (DC) specific enhancer of T cell response
  • NBenefit demonstrated in various preclinical models
  • NClinically validated in 4 ex-vivo DC studies & clinical safety shown for IN

TriMix has unique adjuvant capacity delivering a triple action:

The three mRNA constructs of TriMix code for potent Dendritic Cell (DC) activation molecules: a human Cluster of Differentiation 40 Ligand (CD40L), a Constitutively Active Toll-like Receptor 4 (caTLR4) and human CD70, thereby acting on 3 different immuno-stimulatory pathways.

\

HuCD40L

HuCD40L mimics the interaction between DCs and CD4+ T-cells, activating the DCs to present the antigens. It also leads skewing towards activated T helper 1 CD4+ T cells (Th1) that, through secretion of IL-2, activate cytolytic CD8+ T-cells. CD40L–CD40 interactions mediate one of the most potent DC activating signals

\

caTLR4

caTLR4 mimics the danger signals combated by the immune system upon bacterial infection due to lipopolysaccharide. As such, caTLR4 is a strong activator of the innate immune system and thus of DCs.

\

CD70

CD70 is a member of the tumour necrosis factor (TNF) superfamily of co-stimulatory molecules and is the ligand of CD27, which is constitutively expressed on B cells, naïve T cells, and on several subsets of memory T-cells. Upon T-cell activation, CD27 expression is regulated during several rounds of division and differentiation towards effector T-cells. CD27 ligation promoting the proliferation of primed T-cells is a key contributor to the formation of effector and memory T-cell populations. CD70 is crucial for priming CD8+ T-cell responses.

Inherent immunostimulatory effect

mRNA also has an inherent immunostimulatory effect that strongly activates the innate immune system, this further improves the effectiveness of RNA-based immunotherapies. Nevertheless, TriMix exerts its strongest effect by in vivo expression in APCs, especially dendritic cells (DCs), of the 3 proteins encoded by its mRNAs. TriMix already showed safety and strong efficacy in humans.

More information about

Antigens

Lipid Nanoparticle Technology